Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
After beating "historical" Xtandi masofaniten fails to beat actual Xtandi.
October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.
Conferences ramp up, and ASH abstracts near.
The group goes after a KRAS-related target on which Boehringer recently gave up.
Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.
RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.
